LLY Stock Sinks Despite Q2 Earnings Beat as Obesity Pill Disappoints

Eli Lilly (LLY) significantly beat Q2 2025 earnings and revenue estimates, reporting $6.31 EPS and $15.56 billion in sales, largely due to strong performance from Mounjaro and Zepbound, and subsequently raised its full-year guidance. Despite the robust financial results, shares declined approximately 12% pre-market as its oral obesity drug candidate, orforglipron, delivered a 12.4% weight loss in Phase III trials, which underperformed elevated investor expectations for a key pipeline asset in the highly competitive GLP-1 market.

Analysis

Eli Lilly (LLY) delivered exceptionally strong second-quarter 2025 results, with revenues of $15.56 billion (+38% YoY) and adjusted EPS of $6.31 (+61% YoY), both significantly surpassing consensus estimates. This performance was driven by the robust sales of its GLP-1 drugs, Mounjaro ($5.2 billion) and Zepbound ($3.38 billion), whose growth was fueled by a 42% increase in volume, which more than offset a 6% decline in net realized prices. The company subsequently raised its full-year 2025 guidance for both revenue and earnings, signaling confidence in its commercial execution. However, these strong fundamentals were completely overshadowed by disappointing clinical data for its oral obesity candidate, orforglipron. The drug's 12.4% weight loss in a Phase III trial, while meeting its primary endpoint, fell short of high investor expectations, triggering a sharp pre-market stock decline of approximately 12%. This market reaction underscores the immense premium placed on future pipeline success in the oral GLP-1 market and reveals a potential vulnerability for LLY, as competitors Novo Nordisk (NVO) and Viking Therapeutics (VKTX) saw their shares rise on the news. The mixed performance of LLY's other key drugs, with Verzenio and Taltz missing sales estimates, further highlights the company's increasing reliance on its tirzepatide franchise.

Key Decisions for Investors

• Investors should assess if the ~12% share price decline represents an overreaction to the orforglipron data, potentially creating a buying opportunity based on the strength of current Mounjaro/Zepbound sales and the upwardly revised full-year guidance.
• Closely monitor the competitive landscape, particularly the upcoming Q4 FDA decision on Novo Nordisk's oral Wegovy and clinical progress from Viking Therapeutics, as these events will directly impact the future market share and pricing power within the lucrative oral obesity market.
• Consider the portfolio concentration risk, as LLY's growth is overwhelmingly dependent on Mounjaro and Zepbound, while sales of legacy drugs like Trulicity and Jardiance are declining and other growth assets like Verzenio missed expectations.